Evidence map›Paper›PMID 32362897›Full record

ArticleFrontiers in immunology2020

Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility Antigens.

Kyra J Fuchs, M Willy Honders, Edith D van der Meijden, Alwin E Adriaans, Dyantha I van der Lee, Margot J Pont, Ramin Monajemi, Szymon M Kielbasa, Peter A C 't Hoen, Cornelis A M van Bergen and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 3 countries.

Kyra J FuchsDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
M Willy HondersDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Edith D van der MeijdenDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Alwin E AdriaansDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Dyantha I van der LeeDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Margot J PontDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Ramin MonajemiDepartment of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands.
Szymon M KielbasaDepartment of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands.
Peter A C 't HoenDepartment of Human Genetics, Leiden University Medical Center, Leiden, Netherlands.
Cornelis A M van BergenDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
J H Frederik FalkenburgDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Marieke GriffioenDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Leiden University Medical Center · NLRadboud Institute for Molecular Life Sciences · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients undergoing allogeneic stem cell transplantation as treatment for hematological diseases face the risk of Graft-versus-Host Disease as well as relapse. Graft-versus-Host Disease and the favorable Graft-versus-Leukemia effect are mediated by donor T cells recognizing polymorphic peptides, which are presented on the cell surface by HLA molecules and result from single nucleotide polymorphism alleles that are disparate between patient and donor. Identification of polymorphic HLA-binding peptides, designated minor histocompatibility antigens, has been a laborious procedure, and the number and scope for broad clinical use of these antigens therefore remain limited. Here, we present an optimized whole genome association approach for discovery of HLA class I minor histocompatibility antigens. T cell clones isolated from patients who responded to donor lymphocyte infusions after HLA-matched allogeneic stem cell transplantation were tested against a panel of 191 EBV-transformed B cells, which have been sequenced by the 1000 Genomes Project and selected for expression of seven common HLA class I alleles (HLA-A

Indexed as

Stem Cell TransplantationAllelesClone CellsGenome-Wide Association StudyGraft vs Host DiseaseGraft vs Leukemia EffectHLA-A AntigensHLA-B AntigensHLA-C AntigensHumansMinor Histocompatibility AntigensPolymorphism, Single NucleotideProtein BindingT-LymphocytesTransplantation, HomologousHLA-A AntigensHLA-B AntigensHLA-C AntigensMinor Histocompatibility Antigensallogeneic stem cell transplantationgraft versus host diseaseGraft-versus-Leukemia effecthematological diseasesHLA class Iminor histocompatibility antigenswhole genome association scanning

Identifiers

PMID32362897
PMCPMC7180171
OpenAlexW3016454533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.